Spinal Muscular Atrophy Clinical Trial
Official title:
Fedt og Sukkerstofskiftet Under Faste Hos Patienter Med Lav Muskelmasse.
In a study from 2003 the investigators showed that adult patients with very low skeletal muscle mass (spinal muscular atrophy (SMA) type II, Duchenne muscular dystrophy, congenital muscular dystrophy) are prone to develop hypoglycemia during prolonged fasting. Since then case reports have described the same phenomenon with hypoglycemia and metabolic crises in children with low skeletal muscle mass provoked by infection, fasting and surgery. Pathophysiological mechanisms of metabolism have never been investigated in adults or children with SMA II. Thus the investigators studied fat and glucose metabolism during prolonged fasting in patients with SMA II and LAMA 2 and compared results to those found in healthy controls.
Design. This is a prospective case-control study investigating fat and glucose metabolism in
patients with low muscle mass during prolonged fasting, comparing results to those found in
healthy controls.
Setting. All children were admitted to the Department of Pediatrics and Adolescents medicine,
Rigshospitalet, and all adult subjects were admitted to the Department of Neurology,
Rigshospitalet at 4 pm for a 24-hour fasting period.
Protocol. The protocol consisted of two visits. A pre-experimental visit and a study visit.
Pre-experimental visit. Total muscle mass presented as lean body mass (LBM) was measured by
DEXA scan. Furthermore, pre-experimental preparations included that all subjects were
instructed to follow national nutritional recommendations with a healthy diet consisting of
less than 30% fat, low fat protein, long chain carbohydrates and minimize sugar intake three
days before the study.
Study visit. Patients were admitted to the hospital at 16:00 hours for IV catheter placement
and a standardized evening meal at 17:00. Two venous catheters were inserted, one in the
cubital vein (for stable-isotope infusion) and one in the distal cephalic vein (for blood
sampling). A heating pad, covering the hand and distal forearm, ensured shunting of arterial
blood to the veins in order to obtain arterialized blood. A primed, constant rate infusion of
[U-13C]-palmitate (0.0026 mg kg-1 min-1, primed by a 0.085 mg kg-1 NaH13CO3 bolus) and
[D2]-glucose (0.0728 mg kg-1 min-1, primed by a 3.203 mg kg-1 D2- glucose bolus) was
delivered by a Gemini PC2 pump (IMED, San Diego, CA). Preparation of tracers and tracer
calculations were performed as described.
Blood and air samples were collected just before start of infusion of the stable isotopes,
and again after 2, 10, 14, 16, 18, 20, 22 and 24 hours of fasting (figure 1). Gas exchange
measurements (indirect calorimetry) were performed with a metabolic cart (Cosmed Quark b2;
Cosmed Srl., Milan, Italy). At the same time-points, expired air was collected in a 15 L
Douglas bag (Hans Rudolph, Kansas City, MO, USA) and 10 mL samples were transferred to vacuum
tubes (Vacutainer, BD, Franklin Lakes, NJ, USA) for 13CO2 analysis.
The blood glucose levels were monitored continuously at all blood sampling times and every
third hour during the night in the patients. If the subjects developed symptoms of
hypoglycaemia (fatigue, dizziness, nausea) the blood sugar was measured immediately. The
fasting period lasted 24 hours or until signs of hypoglycemia as mentioned above or blood
glucose below 3.0 mmol/L. Patients received an IV bolus of 10% glucose according to weight if
signs of hypoglycemia occurred.
Analyses of blood samples and expired 13CO2. Venous blood was transferred to cooled tubes
with EDTA (Ethylenediaminetetraacetic acid) (0.33M, 10μL mL-1) and spun at 4,000 rpm for 10
minutes. Plasma was distributed to Eppendorf tubes and immediately frozen on dry ice and
stored at -80°C until analysis. Plasma insulin and glucagon analyses were performed at the
Department of Clinical Biochemistry at Rigshospitalet, Copenhagen, Denmark (Cobas 8000,
Roche, Rotkreuz Switzerland). Plasma free fatty acids and catecholamines were analyzed by
spectrophotometry (Multiskan GO, Thermo Scientific, SkanIt™ Software, Thermo Fisher
Scientific Inc., USA). Plasma palmitate, β-hydroxybuturate, acetoacetate, pyruvate, glycerol
and amino acids as well as 13CO2-breath enrichment were analyzed by gas chromatography
isotope ratio-mass spectrometry (Thermo Finnigan MAT GmbH, Bremen, Germany). Isotope tracer
enrichments were determined using gas chromatography-mass spectrometry (Thermo Finnigan MAT
GmbH, Bremen, Germany).
Glucose and lactate were analyzed on (ABL 700) immediately as the blood was drawn.
Shofield equation was used to calculate expected basal metabolic rate for the children: Males
10-17 years: (17.7 x weight+657+105) and females 10-17 years: (13,4 x weight+692+112) and the
results were compared with the resting metabolic rate (RMR) measured by indirect
calorimetric, as described above, at the end of the study, were patients had been resting and
fasting for more than 8 hours.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04851873 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
|
Phase 3 | |
Completed |
NCT03223051 -
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Recruiting |
NCT05794139 -
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Completed |
NCT02003937 -
Aerobic Training in Patients With Spinal Muscular Atrophy Type III
|
N/A | |
Not yet recruiting |
NCT00961103 -
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)
|
N/A | |
Completed |
NCT00227266 -
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
Completed |
NCT00374075 -
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
|
Phase 1 | |
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Recruiting |
NCT05779956 -
Personalized Medicine for SMA: a Translational Project
|
||
Recruiting |
NCT03300869 -
Natural History of Types 2 and 3 SMA in Taiwan
|
||
Recruiting |
NCT03217578 -
Neonatal Spinal Muscular Atrophy (SMA) Screening
|
||
Completed |
NCT01703988 -
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02235090 -
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
|
N/A | |
Completed |
NCT02123186 -
Newborn Screening for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00756821 -
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00004771 -
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
|
Phase 2 | |
Recruiting |
NCT05366465 -
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
|
||
Recruiting |
NCT06310421 -
Spinal Muscular Atrophy Neonatal Screening Program
|